At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 201 enrolled
Drug / intervention
LY2495655 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Randomized Study to Investigate the Efficacy and Safety of LY2495655 Versus Placebo in Older Patients Who Have Fallen Recently and Have Muscle Weakness
In Brief
A Phase 2 clinical trial evaluating LY2495655 and Placebo for Muscle Weakness. Completed, enrolled 201 participants across 22 sites in 6 countries.
Detailed Summary
LY2495655 is an investigational drug being tested for muscle wasting.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMuscle Weakness
CountriesArgentina, Australia, France, Germany, Sweden, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2012
First PostedMay 2012
Primary CompletionSep 2013
Study CompletionDec 2013
TodayJul 2026
First PostedMay 23, 2012
Enrollment StartMay 1, 2012
Primary CompletionSep 1, 2013
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 14.1 years ago
Interventions
LY2495655biological
Administered SC
Placebodrug
Administered SC